---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-000405"
form_type: "8-K/A"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2026-01-23T23:59:59+00:00"
generated_at: "2026-05-16T08:38:10.260855+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# BioCryst appoints Dr. Jill Milne to Compensation and Science Committees following Astria merger close

## Summary
- Merger with Astria Therapeutics completed on January 23, 2026; Astria becomes wholly owned subsidiary.
- Dr. Jill C. Milne appointed to BioCryst Board of Directors effective as of closing date.
- On January 20, 2026, Board appointed Dr. Milne to Compensation and Science Committees.

## SEC filing metadata
- accession: 0001171843-26-000405
- form_type: 8-K/A
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2026-01-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184326000405/0001171843-26-000405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184326000405/f8ka_012226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-000405
- JSON: https://secwatch.observer/filing/0001171843-26-000405.json
- Plain text: https://secwatch.observer/filing/0001171843-26-000405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.